Dr. Christopher Starr discusses a new Harris Poll survey from the American Academy of Ophthalmology that uncovered significant gaps in Americans’ knowledge that could leave their eye health at risk.
Celebrity fitness trainer Anna Kaiser, Founder of AKT, partnered with Lilly in October 2018 to create “The Thriver Movement” She is kicking off the new year with the 30-day Thriver Challenge to help bring awareness and support to people living with metastatic breast cancer (MBC). The purpose of the challenge is to provide 30 days of mindfulness activities and “life hacks” for and by the community coming out of the busy holiday season and into a new year to encourage self-care, empowerment, and inspiration for women and men living with MBC. She is joined by Christine Hodgdon, Patient Advocate for MBC. For more information, please visit: moreformbc.com Provided by Eli Lilly and Company
Start the New Year off on a healthy note. Dr. George Koob, Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) discusses possible signs to an alcohol use disorder (AUD) and if taking part in “Dry January” (not drinking any alcohol during the month) can be a healthy step. He also talks about the newest treatment options now available, including medication and behavioral treatments by health providers and the role of mutual support groups.
Curtis Gattis, Co-founder and CEO of LeadingReach discusses the company’s low cost, high-value software solutions that empower healthcare professionals to ensure patients get the right care from the right providers faster, easier, and more cost-effectively than ever before. From the largest health systems to independent offices LeadingReach helps care teams more effectively communicate with each other while monitoring and facilitating care transitions. The company also empowers patients with a better experience and access to happier, healthier lives.
Tzvia Bader, co-founder, and CEO talks about TrialJectory, a first-of-its-kind AI-powered platform that uses self-reported clinical data to match cancer patients with clinical trials and removes barriers to advanced treatment options. Tzvia is a cancer survivor and knows first hand what it’s like to be in search of the right clinical study. This service will allow all patients, regardless of where they are or their income level, to have access to the most up-to-date treatments.
Matthew Bauer, L.Ac., President at The Acupuncture Now Foundation, a non-profit organization discusses the practice of acupuncture, the foundation, and their mission to bring accurate up to date information and resources to health professionals and the public. He also talks about how acupuncture works with mainstream medicine.
Alison Corcoran, EVP and Chief Marketing Officer at DentaQuest, discusses the gaps in dental care in the U.S., the future of oral health in this country, and what can be done to change a system that is failing millions of Americans.
Theresa (Terry) Hush, CEO of Roji Health Intelligence, a company that is helping to improve the quality of healthcare by enabling better decisions through integrated data, discusses her mission to give doctors/healthcare providers the right information to make smarter patient decisions while reducing healthcare costs. She also talks about why patient experience needs to move beyond convenience and responsiveness.
Roughly 75% of the earth’s surface is covered by water, yet the ocean remains largely unexplored for drug discovery. Gloucester Marine Genomics Institute (GMGI) scientists are excited to lead the charge in exploring the ocean’s microbiome to provide research to inform treatments – possibly cures – of devastating diseases. Dr. Andrea Bodnar is here to talk about some of the latest marine research and its look at anti-ageing and human health effects.
Dr. John Albert, a rheumatologist at the Rheumatic Disease Center in southeastern Wisconsin, discusses a new in-practice patient series presented at the American College of Rheumatology (ACR) Annual Meeting 2019. The series looked at how methotrexate may attenuate the immune response to KRYSTEXXA to allow more patients on KRYSTEXXA to continue their treatment, helping to inform rheumatologists on effective treatment practices to control the serious and chronic disease of gout.